腺病毒介导的VEGF基因转移 (121) 改善下肢内皮功能和流量储备
S Rajagopalan1, M Shah, A Luciano
1Department of Internal Medicine, University of Michigan, Ann Arbor, USA. srajagop@umich.edu
Circulation
|August 15, 2001
概括
血管内皮生长因子 (VEGF) 的腺病毒基因转移改善了外周动脉疾病患者的下肢血流和内皮功能. 这种基因疗法增强了血液流量储备和行走能力,显示出治疗这种疾病的希望.
科学领域:
- 分子生物学和遗传学 分子生物学和遗传学
- 心血管研究的心血管研究.
- 再生医学是一种再生医学.
背景情况:
- 血管内皮生长因子 (VEGF) 正在研究其在外周动脉疾病 (PAD) 血管生成中的作用.
- 腺病毒载体正在临床试验中被探索用于向基因传递.
- 这项研究研究了VEGF基因传递对PAD患者内皮功能的影响.
研究的目的:
- 为了评估由腺病毒介导的VEGF基因传递对外周内皮功能的影响.
- 评估下肢血流和血管扩展剂对内皮细胞反应的变化.
- 确定VEGF基因转移是否可以改善PAD的内皮功能和流量储备.
主要方法:
- 一期临床试验,涉及腺病毒介导的VEGF基因输送到下肢.
- 在基线和治疗后30天使用热稀释测量下肢血流量.
- 通过输入内皮依赖性 (乙胆) 和独立性 (尼甘油) 激动剂的股骨动脉输注来评估内皮功能.
主要成果:
- 在对乙胆的反应中,VEGF的腺病毒基因转移 (121.10) 显著增加了血液流动.
- 酸甘也显示治疗后血液流量增加,尽管与基线相比,在统计学上并不显著.
- 所有患者的下肢流量储备改善,治疗后的高峰步行时间增加.
结论:
- 在患有外周动脉疾病的患者中,VEGF ((121.10) 的腺病毒基因转移有效调节内皮功能.
- 基因治疗方法显示出改善下肢血流和功能能力的潜力.
- 这项研究支持VEGF基因疗法作为增强PAD血管功能的可行策略.
相关概念视频
Regulation of Angiogenesis and Blood Supply
2.9K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.9K
Vascular Resistance
14.0K
Vascular resistance is a critical concept in understanding blood flow dynamics in the circulatory system. It refers to the resistance that blood encounters as it flows through the blood vessels. This resistance is a key factor in determining blood pressure and cardiac workload.
The primary determinants of vascular resistance are vessel diameter, blood viscosity, and vessel length. Among these, vessel diameter plays the most significant role due to the fourth power relationship described by...
The primary determinants of vascular resistance are vessel diameter, blood viscosity, and vessel length. Among these, vessel diameter plays the most significant role due to the fourth power relationship described by...
14.0K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
614
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
614


